Shares of Zoetis Inc (NYSE:ZTS) have been given a consensus recommendation of “Buy” by the twenty brokerages that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $73.72.

Several brokerages recently commented on ZTS. Piper Jaffray Companies reiterated a “buy” rating and set a $86.00 price target on shares of Zoetis in a research report on Thursday. Jefferies Group reiterated a “buy” rating and set a $89.00 price target on shares of Zoetis in a research report on Tuesday. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target for the company. in a research report on Saturday, January 13th. BMO Capital Markets boosted their price target on Zoetis to $78.00 and gave the stock a “market perform” rating in a research report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $85.00 price target on Zoetis and gave the stock a “buy” rating in a research report on Thursday, January 11th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZTS. Cibc Bank USA acquired a new position in shares of Zoetis in the 4th quarter valued at $226,000. State of Alaska Department of Revenue lifted its stake in shares of Zoetis by 1.5% in the 4th quarter. State of Alaska Department of Revenue now owns 185,981 shares of the company’s stock valued at $13,396,000 after purchasing an additional 2,700 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Zoetis by 111.3% in the 4th quarter. Acadian Asset Management LLC now owns 1,709,352 shares of the company’s stock valued at $123,143,000 after purchasing an additional 900,261 shares during the last quarter. Westpac Banking Corp lifted its stake in shares of Zoetis by 5.4% in the 4th quarter. Westpac Banking Corp now owns 315,647 shares of the company’s stock valued at $22,739,000 after purchasing an additional 16,300 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of Zoetis by 6.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,745,887 shares of the company’s stock valued at $125,774,000 after purchasing an additional 111,513 shares during the last quarter. 93.14% of the stock is currently owned by institutional investors.

Shares of Zoetis (NYSE:ZTS) traded up $0.29 on Friday, hitting $76.62. The company had a trading volume of 3,476,402 shares, compared to its average volume of 1,950,000. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a 52-week low of $52.00 and a 52-week high of $77.03. The stock has a market capitalization of $37,340.00, a PE ratio of 40.33, a price-to-earnings-growth ratio of 1.83 and a beta of 1.06.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the business earned $0.52 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. sell-side analysts predict that Zoetis will post 2.36 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.66%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s payout ratio is 26.32%.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/01/20/zoetis-inc-zts-receives-average-rating-of-buy-from-analysts.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.